-
Grand Pharma Completes Patient Enrollment for STC3141 Sepsis Study
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that all patients have completed enrollment and dosing in the Phase Ib REFINE study for its drug candidate STC3141 in sepsis in Australia and Belgium. The first data readout is expected in four months’ time, marking a significant milestone in the…
-
Eyebright Medical Gains SIX Swiss Exchange Approval for GDR Offering
•
Beijing-based ophthalmic device maker Eyebright Medical Technology Co., Ltd (SHA: 688050) has announced receiving conditional approval from the SIX Swiss Exchange to make a public offering of an undisclosed amount of Global Depositary Receipts (GDR) on the bourse. This marks a significant step in the company’s international expansion and capital…
-
Teddy Clinical Research Lab Partners with Cerba Research for Global Services
•
China-based Teddy Clinical Research Laboratory Limited, a joint venture (JV) between Dian Diagnostics (SHE: 300244) and Tigermed (SHE: 300347, HKG: 3347), has struck a partnership with Belgium-headquartered Cerba Healthcare’s subsidiary Cerba Research. The two companies will set up a JV in Wuxi, Jiangsu Province, China, marking a significant expansion of…
-
Junshi Biosciences’ COVID-19 Therapy Faces Supply Issues, Partners with Sihuan Pharma
•
Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) appears to be facing supply issues, prompting the company to seek additional production and supply agreements. The latest deal was struck with Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), following a similar agreement with Zhejiang Huahai Pharmaceutical Co., Ltd (SHA:…
-
Macrolux Secures Series A Funding for Endoscopy Solutions
•
Macrolux, an endoscopy intervention solutions provider based in Shenzhen, has reportedly raised close to RMB 100 million (USD 14.75 million) in a Series A financing round. This significant capital injection will support the company’s efforts to provide solutions better tailored to customer needs globally. Financing DetailsThe Series A round was…
-
Hua Medicine Receives Milestone Payment from Bayer for Dorzagliatin
•
China-based Hua Medicine has announced receiving a RMB 400 million (USD 59 million) milestone payment under the terms of a cooperation deal with Bayer (ETR: BAYN). The payment is related to Hua’s first-in-class glucokinase activator (GKA) dorzagliatin, which was approved in China in October 2022 for the treatment of metformin-tolerant…
-
SciClone Pharmaceuticals Files for Hong Kong Market Approval of Danyelza
•
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017, has announced that a market approval filing has been made in Hong Kong for its Danyelza (naxitamab) in recurrent or refractory high-risk neuroblastoma. This marks a significant step in the global expansion of this innovative…
-
Asia Regenerative Medicine Raises Pre-Series A+ Funding for Bioartificial Organs
•
Shenzhen-based Asia Regenerative Medicine (ARM) has reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing round led by Efung Fund, with participation from True Trust Investment. The proceeds will be used to advance large animal experiments, investigator-initiated trials (ITT), and Investigational New Drug (IND) filing preparations. This…
-
Beijing Smart Beam Raises Series A+ Funding for CT X-Ray Tube Development
•
Beijing Smart Beam Technology, a leading vacuum electronic device maker, has reportedly raised “tens of millions” of renminbi in a Series A+ financing round. This significant capital injection was led by Waldorf Capital, with contributions from Hainayourong Investment and Jiagengxin Capital. The proceeds will be directed towards CT X-Ray tube…
-
Asieris Partners with ReviR Therapeutics for Urogenital Cancer Research
•
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has struck a partnership with compatriot firm ReviR Therapeutics, an artificial-intelligence (AI) and gene tech-powered start-up. The collaboration aims to utilize ReviR’s in-house developed AI drug research and development (R&D) platform and targeted RNA technology to conduct research…
-
Siemens Healthineers Reports Q1 Revenue Drop Amid COVID-19 Impact
•
Germany-based medical device giant Siemens Healthineers AG has released its fiscal year 2023 Q1 financial report for the three-month period ending December 31, 2022. Global revenues were down 4.5% to EUR 5.077 billion (USD 5.5 billion), primarily reflecting the slowing demand for COVID-19 antigen testing. Business Group PerformanceExcluding COVID-19 antigen…
-
Astellas Pharma Reports Strong Q3 Results with 17.3% Revenue Growth
•
Japan-based Astellas Pharma Inc. (TYO: 4503) has released its financial report for Q3 of its fiscal year 2022, which ended December 31, 2022. The firm’s global revenues over the 9-month period reached JPY 1.164 trillion (USD 8.79 billion), marking a 17.3% year-on-year (YOY) growth. Top Performers and Sales DataAstellas’ top…
-
Harbour BioMed’s Anti-CCR8 Monoclonal Antibody HBM1022 Receives FDA IND Approval
•
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China, has announced receiving Investigational New Drug (IND) approval from the US FDA for its in-house developed HBM1022, a novel anti-C-C chemokine receptor type 8 (CCR8) monoclonal antibody (mAb). This marks a significant milestone in the…
-
Eli Lilly’s Tirzepatide Achieves Primary Endpoints in Chinese Obesity Study
•
US major Eli Lilly (NYSE: LLY) has announced that the Phase III SURMOUNT-CN study for its glucose-dependent insulinotropic polyptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide has reached the primary endpoint and all pivotal secondary endpoints in obese or overweight Chinese adults. The study demonstrated that the overall safety profile was…
-
Lifetech Partners with Jenscare for Structural Heart Disease Devices
•
China-based Lifetech Scientific Corporation (HKG: 1302) has announced a partnership agreement with compatriot firm Jenscare Scientific Co., Ltd. This strategic collaboration aims to enhance the development and marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. Partnership DetailsJenscare, based in Ningbo, is focused on…
-
Gracell’s CAR-T Therapy GC012F Receives FDA IND Approval
•
Shanghai-based biotech Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the US FDA for its chimeric antigen receptor (CAR) T cell candidate GC012F. This dual BCMA/CD19-targeted therapy is set to be assessed in treating relapsed/refractory multiple myeloma (r/r MM), marking a significant step forward in the development…
-
Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results
•
US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial results. Global Q4 sales reached USD 7.4 billion, up 2% year-on-year (YOY), while full-year revenues topped USD 27.3 billion, flat with the previous year. Gilead issued guidance for 2023 product sales to range from USD…
-
Sanofi Reports Strong Q4 and Full-Year 2022 Financials with 7% Growth
•
France’s Sanofi (EPA: SAN) released its financial report last week, showing turnover during Q4 and full-year 2022 at EUR 10.7 billion (USD 11.6 billion) and EUR 43.0 billion (USD 46.4 billion) respectively. This represents year-on-year (YOY) growth of 2.6% and 7.0% at constant exchange rates (CER). The results highlight Sanofi’s…
-
Sanner Group Prepares to Open Second Manufacturing Facility in China
•
Germany-based Sanner Group, a specialist in medical devices and pharma packaging, has announced plans to open a second manufacturing facility in China. This expansion comes alongside the existing facility in Kunshan, Jiangsu Province, and follows the groundbreaking for a new global headquarters and production site in Germany. China Facility DetailsConstruction…
